Study on Novel Strategies for Cervical Cancer Screening Using Photoelectric Detection and Epigenetic Procotol

Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Mar 4, 2025

Keywords

ClinConnect Summary

This clinical trial is studying new ways to screen for cervical cancer and related conditions using a combination of tests. The goal is to see if these new methods can help doctors find more cases of serious pre-cancer (called CIN2+) and reduce unnecessary procedures for women. The study will involve around 4,200 women across multiple centers, who will be divided into two groups. One group will undergo a standard test, while the other group will receive an additional test to improve accuracy.

To participate, women need to be between 18 and 65 years old, have certain high-risk types of HPV (the virus linked to cervical cancer), and have never had cervical cancer or treatment for it. They must also not be experiencing any acute inflammation in the cervix and should be willing to give their consent to join the study. This trial is not yet recruiting participants, but if you meet the criteria, this study could offer a chance to contribute to important research aimed at improving cervical cancer screening.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Women between the ages of 18 and 65 who have already had sex life
• • 2. HPV16, 18 positive or high-risk HPV infection with cytology ≧ASC-US
• • 3. No history of cervical cancer and cervical physical therapy, a complete cervix
• • 4. No menstrual period, no sexual activity and vaginal medication within 48 hours
• • 5. The vagina or cervix is not in a stage of acute inflammation
• • 6. Willing to participate in the study with full informed consent
• Exclusion Criteria:
• • 1. Cervical dysplasia (congenital malformation or double uterus, etc.)
• • 2. History of cervical treatment (coning, ablation, or photodynamic therapy)
• • 3. There are definite immunosuppression conditions, such as HIV infection or organ transplantation
• • 4. Patients with severe bleeding diseases such as coagulation abnormalities or photosensitive diseases (such as porphyria, lupus erythematosus, etc.)
• • 5. A history of radiation or chemotherapy (e.g., pelvic radiation therapy) with cancer at other sites
• • 6. The patient is in pregnancy or puerperium
• • 7. The other conditions of this study were not considered appropriate by the researchers